0001104659-23-129007.txt : 20231226 0001104659-23-129007.hdr.sgml : 20231226 20231226083530 ACCESSION NUMBER: 0001104659-23-129007 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20231222 ITEM INFORMATION: Other Events FILED AS OF DATE: 20231226 DATE AS OF CHANGE: 20231226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Immunome Inc. CENTRAL INDEX KEY: 0001472012 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 770694340 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39580 FILM NUMBER: 231511417 BUSINESS ADDRESS: STREET 1: 665 STOCKTON DRIVE STREET 2: SUITE 300 CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 610-321-3700 MAIL ADDRESS: STREET 1: 665 STOCKTON DRIVE STREET 2: SUITE 300 CITY: EXTON STATE: PA ZIP: 19341 8-K 1 tm2333682d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 22, 2023

Immunome, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39580		77-0694340
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

665 Stockton Drive, Suite 300 Exton, Pennsylvania		19342
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (610) 321-3700

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		IMNM		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events.

On December 22, 2023, Immunome, Inc. (the “Company”) announced that it had reached agreement with Atreca, Inc. (“Atreca”) on the terms of a cash acquisition pursuant to which the Company would acquire certain antibody-related assets and materials for an upfront payment of $5.5 million and up to $7.0 million in clinical development milestones. The closing of the transaction is subject to customary conditions, including the approval of Atreca’s stockholders.

In addition to historical facts, this Current Report on Form 8-K contains forward-looking statements that involve a number of risks and uncertainties. The Company’s expectation that the purchase of assets from Atreca will close; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, the risk that the transaction with Atreca will not be completed, the Company’s ability to grow and successfully execute on its business plan, including advancing its current pipeline and any additionally acquired assets into the clinic and expanding its pipeline through its technology platforms, proprietary toolbox and the Atreca transction and other strategic transactions, if any; the ability of the Company to identify, conduct and complete IND-enabling studies; changes in the applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; the risk that regulatory approvals for the Company’s programs and product candidates are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect it or the expected benefits of the Atreca transaction; the Company’s ability to manage clinical trials or studies; the risk that pre-clinical data may not be predictive of clinical data; the complexity of numerous regulatory and legal requirements that the Company needs to comply with to operate its business; the reliance on the Company’s management; the prior experience and successes of the Company’s management team are not indicative of any future success; uncertainties related to the Company’s capital requirements and the Company’s expected cash runway; the failure to obtain, adequately protect, maintain or enforce the Company’s intellectual property rights; and other risks and uncertainties indicated from time to time described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with Securities and Exchange Commission (“SEC”) on March 16, 2023, the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 filed with the SEC on November 9, 2023, and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive and not to place undue reliance upon any forward-looking statements which speak only as of the date made. Moreover, the Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Except as required by law, the Company does not undertake any obligation to update publicly any forward-looking statements for any reason after the date of this Current Report on Form 8-K to conform these statements to actual results or to changes in their expectations.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		IMMUNOME, INC.

Date: December 26, 2023		By:	/s/ Clay Siegall
			Clay Siegall, Ph.D.
			President and Chief Executive Officer

EX-101.SCH 2 immu-20231222.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 immu-20231222_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 immu-20231222_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT

Cover	Dec. 22, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Dec. 22, 2023
Entity File Number	001-39580
Entity Registrant Name	Immunome, Inc.
Entity Central Index Key	0001472012
Entity Tax Identification Number	77-0694340
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	665 Stockton Drive, Suite 300
Entity Address, City or Town	Exton
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19342
City Area Code	610
Local Phone Number	321-3700
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	IMNM
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

XML 6 tm2333682d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001472012 2023-12-22 2023-12-22 iso4217:USD shares iso4217:USD shares false 0001472012 8-K 2023-12-22 Immunome, Inc. DE 001-39580 77-0694340 665 Stockton Drive, Suite 300 Exton PA 19342 610 321-3700 false false false false Common Stock, $0.0001 par value per share IMNM NASDAQ true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://immunome.com/role/Cover Cover Cover 1 false false All Reports Book All Reports immu-20231222.xsd immu-20231222_lab.xml immu-20231222_pre.xml tm2333682d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2333682d1_8k.htm": { "nsprefix": "immu", "nsuri": "http://immunome.com/20231222", "dts": { "schema": { "local": [ "immu-20231222.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "immu-20231222_lab.xml" ] }, "presentationLink": { "local": [ "immu-20231222_pre.xml" ] }, "inline": { "local": [ "tm2333682d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://immunome.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-12-22", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333682d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-22", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333682d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://immunome.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0001104659-23-129007-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-129007-xbrl.zip M4$L#!!0 ( &Y$FE=_=Y5<*0, .,+ 1 :6UM=2TR,#(S,3(R,BYX M],_T'U:\8V-I,F$$@FI9.$E%P*39KFI2-L 1IDR97D0/KU ME6S+7 P$:,N3M'O.V5UI5Z9Q-HT(>$%<8$:;EN=4+(!HP$),ATWKH6>?]UKM MM@7.3M^_ ^K7^&#;X (C$M;!9Q;8;3I@)^ 61J@.+A%%'$K&3\ C)(FVL M, M$ PO=1T1#QA^Z[4)W)&4LZJX[F4P3HVD7/PT1/4XZL/HMZ\O^ M7?C[N7L ?XRG,OITU'^D7ZY>O\JKZUO9[]%1#5Y='C^-[[.0#1&,4 2!N@PJ MFI:N+R]O4G48'[I^I>*Y3S>=7HJS,F!]2C =KX)[M5K-3;T&6D).^YP8Z:JK MW7TH4*&LO'@#'E,A(0T6\*$L"//@0S=S+D#Q2NC'#(H--$1+.($"9\A>7.50 M>+]J@(FPAQ#&!7@ 13\5S1T+8,%E&:B,RR!;OL9(K(1FK@4"CJ*DP.H-91'2 M/9FB/-_WU601%"$J+QB//J,!3(A*Y%<""1Y@%%I 0CY$4C>9B&& WE SG0HI M9:JAU53E%FV+8ZPZMC HD[[A.F<$?5.I [U0$[4ZA':Z+:9>!0O@L&EERSDQ M(Q>B :8X#9U/D =L/2^)+E,M4V;#70:7E1*!PCMZFJYCCH2BIR5UE"'GYY#- MW "2("%[46?Y;6+F=G.0I1,V@]1% Y .8%VW2M,26#^!5FX;<31H6OK0;7.? M/U79CFHE ]$1-@Q@>D?+)Y4'-A*0!R65T@.A1%B,N,2JG^=>@2QU+#7]?BX, MT'&$!=Q_6#F!_5TK5Q1$_F/)':U?KK7A+DZ6VB]/7T.5R[@$M#3&FU[1[/WO ML""5VD#1.]OP;&VR/=^N>LY4A+-,=TEB=@*[)6%X>R2QYBU?%5^L@^M%VD+; M!EWS3=@8="7'140*8]D[A?DOR%_DD,KLE,3"=8:2NUI"B_JVNL>JMSZ=MYCI M7NS5! %+J.2ONS3"/,5L]KN-V;=_NXLP^.P2]-^!?ZJ7XF*2^CC_^N-M0]$)$FG#V M:71R=#Q"A$4\3MCZT^CK8GRQF,WG(Y1FF,68]CECVGYY/)Z^OK$>,O^)6+I_0HXIMA M%2XRG&W3JK;CW7'YIPC_2!/V=*[^6N&4('F\6'J^2Y-/([7?OIT=YO:N>82SO-M[=X- A?K?6,O&:M/X9#H^/3G:I?%('_S\" I. MR3UY0'DSS[/]LT0I310)HW+;HR /=C-4B(F*GS"RQAF)U8[.U(Y._J%V])=R M\S5>$3I"2BGY -MUUJBK#)JX-GM'1,+C2_8^UV:T)_ORNR.R_Z$!]7CG35CR M#--WF:]'.K=]0]YWQ ]Q[H^T'.?)^XYT+?+_8CMK6W[SX;4?5ZHV7LM/#8MD ME\D)C,3:I*JB8P3.]Y!/#&7=5>T\:M1+U6C.1;OM:F;,ZTQ)=+3F+Y.8)++N MZ:GZ,%8?\F;+__PQXW(E<+%*,X&C3->4-^/3R%(^,2TIY870OK"(>AI7*B81 MEU/3 T89,D)1O143>U"MUM]!1 M*AUMJ%2H)15AXZ^+T0^Y!OVN5?_Y.#G4XJ"CY1)HNR$L6\H:+2UH%KOJ9ILI MW MKC1(B7QU\Q>21B)Y5LOYKG8T9,X[W6*RU?[).U-2B M+*CS6Z(V=@QC@-[UT-]IVYP+K.(@H!GB$)PMZD&HBO+$T05C6TSOR3,77?@T M9:ZIL9DT8:EK@F+$8@Q$H]"B0NR)B%^W\HR="+KOA:*E=,T%8-5$PY %18?= M&PA()??+R%)@EB9J .N%I"UU?KH!F&V=>ABZH#@!S,&G))7>+RF+1T*INA^ M6?^ 8A.[I@4V;/+25@9%#&@/9":/0&5(.-A\3GI;M+GXJ M<; (F0X'4I2'(17GB:3:;8@>AEI*U_0 5DUN#%E0Q-B]@:P4)! MB%0Z/X 8-NUXE*( X6@ZZT-#JGV"<96D$::%ERNY+>UHGD7K&A#0K@E)2Q@4 M*) [$)8B0#.3AW@%YE\$BV&XU)1^8&E9M:-2R0($Q?36AXG2>X%DMA6BX1J> M<6"ILYNR/6:K^[. +@A0>LRU[MH6\@8HGF:@2Y8EV5X]3W>SW:R(L#2N+7'% M!F1.,V&6!\$"8,IDH) AI4.%T$O/Z[L$+%,/,8+-,65N";";;%+0U 1$@M48 M0,-!FS]3ZH6(F1R9!*9S%I/=SV0/MJNE<\L$8+,)A2$*B J[,P"+4HQR-9)R M+V#K>P]-AN,@.( T*GVR% D Q"S2B?(,U9Q,4SKSWN,.-;.0#N9SR& M5R@]46ZA&M2$)EJ=(0$!-L0G@%DC]$/Q3 KBZCV>O *D:O!"W$4Z!9OO) H#E]0U-/_4-S.A2:TZ"A.7T7-++CO8XU,_GQ5BSYJ^WA;%#I M!9FV52LP!UEXN+2\]<&B M1Z1H7XQ"1?6-V*.\%?$A;!2V9([@48P+25&D,; M'CIV@WW\5 MB'>=UK"D6Y;U?$BWS,\HT3=J'F$(3'B1-8[V#2Z'VB<0=3S-, M_YT\=YZ(V\5>\+ :MD+24(:'BLU>'S!%#))!/DZL2US5#0WKJV1&N;M7@"VV M#J\ UPJ#@,#FJ/T*<''UI!"Y[F;%J" 8&!&:QRTU/K[(*KL+O7OD#'Y H"UQU=.0.=W;9GD0/0Z8,GL]EZ%X511$[W8Q?;.9INB7B3?!80CPA!)H'0&KI0\0),MD+51'HDZT%B;9R M?MR?3%?+)*.VD\NVQ-F_T=>>AOS+7?0H31'@A02[S/70;S-I#O]U31 (=!AK MG9244J2U/EY(.$Q9Z_Y%P-K;(F#=LPA8A[@(6 ]=!*R]+0+T;HL4(7).&54(.L2XSFB9ISA3Z?G%)M__E?Q@:26@ M'^(,UH&FJ_ Z=&'P= PDRV"?-"TC=.MRS# M(G^77-A&)D#GEAS 9I,80Q00*79G "&5&!5J/R]H%]DCJD56\;M#8 ,AN>/7 MM3M-&V]M6[4!,=-I$'J'N\SY<5@;%U&>7K',B/J]B.2%?,$9+KV![87DKE^J M[#)MODUITP:$4*=!\/W)*D:EBL&:*6\I8\1,+K76O.,I<4/E/G%,RV([=TPE M"0@/FZ^.##("::T7%A8;3.GG;9HPDL(3D:%RRX+58I.%AB0@%FR^ !9R*=): M+RQ<;HA8R^GM)\%?L\8U1WWZ(&@::-)D*@]KGESG@4A%^LQF M5$]N#R_Q&B+'*V.+06-A7%,$P0AH"UH6UW\KP$_NO.V*)M$5Y1B^RM+0.,Z8 MU[9G),L[" (BH.T*2I&7"U&N]-+_GS%[$MOG+-K?"1X1HIZR2JO1JN_ZV\!H MM\R\J4E-F@:%!L396_P"!!ZJ0+4Z/M1F+)\7\]1#XRJ;&X^>%H]8'L#;;9:J M&50:@Z^"=P8YOKTPH '&38:.B(#0&V 3NN&01Z(\] ,J@E$MVM/Y67K( DCB MS_M[\D"$>N]@27;99[FCIXXSC &QKL_>!C?'/)GK#0P"PK>ZA4[U4E2O *W4 M,V)E%>AW50G*:[']?GE]T[7\)#?K3?*O%4Z)W/)?4$L#!!0 ( &Y$FE>1 MR7FS5 < -57 5 :6UM=2TR,#(S,3(R,E]P&ULS9Q=<^(V%(;O M.]/_X-)K()!NVV23[B1LV&$VNTE#=K?MS8ZP!6@B2XPD!_CWE6S,\F'))S<^ MR45"S*N/]SFV[&-+OGBW2GGT3)5F4ERV>IV35D1%+!,F9I>M+^/VU7@P&K4B M;8A(")>"7K:$;+W[Z^>?(OMS\4N['0T9YCS;G>Y7':$?"9+J9YT)Y8IK,*Q(2;3V]I.5B>;GZ+X!6?BZ=S]FA!-(\M+ MZ/.59I5I1ZI9MW]RTNO^\^EV',]I2MI,.&XQ;96E7"U5Y7IG9V?= M_-M2>J1<310OVSCMEMW9UFR_90']3D\T.]=Y]VYE3$P>]MIF(J_"_=3^VNAM6V5IF@F94A>PKONR.Y!VA[0]S8O- M%9U>MIS(UMX_[?7[?5?WKWLBLU[8'5,SMU^UHNY>NPM%-14FMWIK-^P5H2MC M=R>:E!6Y]J$],\PX\69GZ45MMV=EJ6W+?BR4FXZ47>$RWFN=NPC( ZOEWIQS MUC3NS.1S-Z&LZ^R[#SF'G(']YWO>T-5$&T5B4];$R83RO/[O5G,@Z3;0JY+$ MHZVQNE/[BL,^[0;M2L615 E5EG59%U'Q7JB.=\R-HKL@RE;4CN>,;Z,\53+U MT=F0D)Z.[H*R331#\\JVG[@^##F95>,\D !Y]C" 5KK!(OJ>ZEBQA>-2 W9/ M">3;1^5;X:UAS.6Q\T!GS/77=<6=;JG;&!X7/$6 X$\Q1XJ@6Z0(7 F1$?Y M%U+5@-]7 GG_ALF[RAL2YK\SH@Q5? TA?20&PGZ#"=OC$(GWHR)",\<' OQ8 M#23^.^J%A\*R<2>TA6 _9$82/T,D[K'(2KO&Y% :6^EX/P''_:!/234 M0Z9CPHL>#>TV'<9=(8!]:,('XF$KC[2=0CTD11*&B7'#-I#07VO6$K4>LSB M^D'C6 N%C9)9A@VBT'XDJU%B7;$I*QX&UD/W%H&R1TDK07910C 2L50+N7.[ M>" S>SRN!S()#NDU!:'A0,DW7V =)2A726)QZ (V M7PGV_LNP]^'84?+06INO!/OIR["?PK&CY**U-C&Q#^S'._4HEYXGT%XQ%#E* M+EIC$1-X?J:Y4_=*/K-B3E0=]:,24/2(*6K8+.H.7YSD(7M[J83R1DQ7J\UA M?8>C>>IF$<*Q8N2_@7M-8QZ+#F+F6%B]LE> M(2I&>#7G*AT4,DJRYS?6,.%[15VDJ;WLSN=QN94&ZFXZ]8V\(3V4.$JN5V\4 ME_Q(ZXRJE_*O* 6- DK:!S7=]#A#X\P.>^M>?_+H5LQX1IDC%90U2LKG,]4P MV\_R41&W5F^\3B>2^Y>'5 JAA%$2O("UAB'O]:,:[X$$"A8ELZNT@S0FW*SB M.1$SZI^]4*V$ D;)]$+FT,;>&6CLG;UP[$7)^'RFD-@6<\/M$74WX6Q&_"O) M@@7 ZVPPB0>L-KU^+U_RXU9QJS3OQ]!^J,;ND4*!XRR1#-EK&G66,$.3HDM# M)HB(;4JU7=?FR<[K2T$#@+.&$F@:Y?;^-\KY1R&78DR)EH(FQ:5^Z Z_MP@T M"HC/$&OLHH3@J^29I:3RB:#*Z7MBR*:'(?Z^$E#^B \4PV;1YL^K@3WQS&3XF?F! M$$H;<2ILI344R..4<'Z=:2:H#HXM!T(H9,0YKY764"#?I%3-[*#V0PI H2/.; U:Q8&_^K&.O%C_%B1?H0:_G0 1N]S]M\8W[Y=[!:K?\#U!+ P04 " !N1)I7]SE#;R 7 "# M< $@ '1M,C,S,S8X,F0Q7SAK+FAT;>T]:U?BRK+?78O_T)>S]UG..O(6 M5'0X"P%G,S.B(\[SBZN3-! -24QW!.;7WZKN!!((B(C.['WO[#TB2:>JNMY5 MW9TY^>]X:)$'YG'3L=^F"]E\FC!;=PS3[K]-^Z*7.4S_MY;:.1D(& =C;?XV M/1#"K>9RH]$H.RIE':^?*QP='>7&.":M!E7'B>.*^7PA]^W\8U[TZ&:9YFQH7@E1%+*+8"&N\;L@>C@2D[=C T5B4/+:J@( MAYK[3L/C\(YS)0*(9P%X<1GBK M*);"@1[K+05;R<'=<*#/,WU*W>G@'N6:'!C M))GBX&;L >Z)1=!P,3;(' []Z2C\8CM#EM6=H1Q5*!:+:6E-Q_>IAN.+9@M,M<3%[BMJV]OTX*-14[98 Z?RP5@ M3_XGDR%G)K.,*NDR<4PZ=,BJ9&R,CTF[*7^YR1<;-Y^[?Q:;[^KU2_A \D@F ML^[3I<8-SNXF.L6;<(I/@+-_-GUJD\?+1S<,M OHA__K0V8;\%><6;1_TZ,6 M9T\!=1H!U;)!&),&P/*HU;8--O[ )C=Y<&;[!V G3R&Q<@I\;MX4;@+'H!# MI:? *-YT!]1C_*9X(_V@ L+EM:? :2(MEP<@))2X%KCC$A7$PL]C;= _6K MDD+>%>3:',*0#AN1*V=([3UU80\(\,R>5'3#? B?,TSN6G12);9C,WG3'%=1 M8YF'IB"_F8;!;&D8^!4&=OPAP-*5SH_%%7J..K_HH:YD"N#TBFEBPTP!/#.K M,0U(UZ0*G.1BD#8'GJ@3Z=I,*1(QY6+30L3@WY@'(9=Q-0+=:)7+^ @4$!GT MJ@/I(]&Z,J%99,?<2 >W!3B"MVEN#EV+*>,/4,6!*W3<\;T0&PR3,JX&R3PBR6>) :?1_A!GTOS#,W2Y1'P!-A=XZAB+ M5$#4]T23"E:;32&$-+NW\!@HRI*'PCOS9,4(""\&;(SSUK=-Q5@PJ05N#AGE MOL=J@>U584P(++P51X'0EL!7AKP41< $.6AC'#.'L8 'C!O$N,A;?%8: 16. M%[G]=![,TY@$-8*TR2 6F?9C:!_GRSS>),#A_1@7%A@:6&7$!I5+"/W>20Z> MAT_\[\2=\[&E;/DQ+WM,AM3KFW:5H$/.'Q-4QPRUS#YNG7"7VE'8 M&6[^9,J)IVO__E>ADC\^R>$@2$/>=/R(O06(Z =0ZAK 9JBTXE%^#=?]U]/3LXNJZ8P 7%KK ^H#>&JK@N\7S@J M[0-1=4 Z$,8.S#H9 +D,CO) M/&/$I&M-IK.A!@55L;A'$/)*JWTU=[]E:3\*\'"+]KWH?E4A?\7Z)L<6J,!. M2;(>W-IGXN'[Y:&E2V5\1ML@CBU=:P=]L[W43MO6LXMB?D5/L]L:4_ 42#*: MEC_,-T4%#-8L 6RP*VZW(U))^6WUUJ M&.'W)R.-5# A!1F+]>!IZ@MG>LDS^X/@FFR-"5D;"B-$^, \8>K4"L6G^)LD MTBG*4O'/I!C7HT/3FE0?Z]VANL_93R%F/Z"VC@=>5RX>= 6XKX9JFC<<8XDY M??AVWV_1WI7_B6WJ5G%= ]LZ@KF>\X J&_>K:]"&7M:B(_#(ZZ1$PE@M"*A M5TH!A1!JVF.PGB;4F6#J,<&#]J8N57"5.*Z'7TW>&^0II[] '$M(3=<. M#C+YRM%^:?]1X< /;QV7M41.*@1)(\7DUH%LUB.WD,MRPU19[RS3-:-V'02@ M#=5CH>)X#IS=AC,XSSX^&C:K)#LL+K?AQ.[L7]U=&<]U_LD MX$S7*I4RE+/"T>\$F%/3,Q\8R,(WP3^4\BN]D58+=')Y$1C#VX!?+[QK9V0G MS_2]>7'TO> \?"[V-^S"+$&7KK7&,+E5^8=6VUOH'Y63)B$]YX5W">D0N,P5;2PCKT\X+^( M&UL68P.*,0]P/= JTZ4686.F^P)$_IS(#"),[: 0 M?TWLW0!@D@$% 5,NZ^613\&%L)V@.K//X-.L#_/O?QT6"P?'/+4CF,7<@6,S M8LM\;0_S3,M'H1&H$BG8E0&1?G?>BL\"*T:_7H=QR^WVO%\8FS^;E:]:9<- M$L4!(;*0$ <7:E=MGAMOG6/]QPQO-X MTK52$Q+>ZT$V[8SP.4PR3"RH>/4U>G[1"F&^ M@M@0:>#%%GU8K*0 ZU@91Y?(+S'N2(2%2*)2G,M3, 3- E)(4&'F5!=SS:^> M*4#>6.#Z=E#C\62;'][9/_*=2_U+)[F1\160(F*^\9J*YC@6H[;G,CDZ?$Y;-IAI='/3 MXW_T&%^(&UE9Q+TM9+]8#DP1;3"RDH@+B+N% ](XNR+%4CX+ ]_,]>76R04W MT^$-%?QT,=!.HS>H3\[?K'PKZ1*>YJ;];3 M4#7VM]?1HIG+^7;^[UK[7/QS\8DU=(/C_];508IG]77T]?0W& M)NGK;]JL2 MJ'H1PWFLI%ZVMCI;1]UJ&RR^K3O-9^H4Z7+7F#X@ND4Y7UQAGIO=JA1^ M*>4)[<&_)=,\BG,/UU)P"MW)4'.L7;[07?Q=&/>J#,(]7'&E8H%_#=>J;3(: MF'!]YH V[J(OX6]RO H;J4\KE93#G!2*FK27Y)"O[;=_?CD*NGS4U>A../Z[86Y1G M/I!G8+_*9I.%6?YJ='_^_&A?CO1?*\T8K>E:^[QS_@\2$/A22"R6+1R$FAPF M9\LWHEI?J)N?=.KO6\:SUF_132TNW2;1D08GQPUZGW2H%4^U15>J&]0U!13V MY]2[8V+*R86%IVT< 4E,GIX+5_W$!E]B[C_?&@0UM0U,OQG1)D27K72 =Y?: M&0V8W+\TU^&C[^23#?5@ MLDU_;[W_='Y0_]S_4GSA$EIX/EO< 9!(JF1V,;^\>/Y'"/])IMY+L-W43J 3 MN%:J(/L.&R3I>:L=C#R:'!\%]4%O'[BK5Y@GL'5:IJQK HN M[=(WH8>(NH5LLL:?QC5^?#TE6IUF25;W']>L/_CP[9UHOWIOQ/I_',TXU=R+R)7 ME.@Q(+CWL24*="CQREQS4=.6=@&B.EPH)H24BDS+W;C.A_N*@*[P=0P+B#U& M[S(: W<#U+F2VBBR2@(N)&!]9%$EWZI^O\Z6$C!TD 5$1]\VL,/H>%5L@>"A M1LC9VX(-R6$6"O(+F1^W\-0FS[Y@MW4MLEZ@E%B!\,(F"^<[]\CT)"#!@X"I MG5V,PK@Y#;*P1IAXPK?"\1N(_#; U3%1&% H*S"I,"#'H)!X&(3V/297$U2: M4!<>TZD"BXF]A*@N3@%"]$=TD-D/Y<9*2G3*(;NA^KUOAHE()&5032U\)""- MC!S? M0XWL/^M2"CG3& 59$S7@;G,;<"7^6[/ V:# M54TD]4#''^5L.;4#;LU""O IWT7\?QQD\R2\'/.$2[D.U.B6B:LE%I19#\QR M7(D%H# N')OQ;,PS8L&N6PZ7FY=ZJ1W)'TP@BA2.)\70 U8"/%E8-GS/DPM@P0EO&!QN.I-Y'VB35)01Y+$9RW'N@L16 M2$WG@2'8#X[U )P.=G#*8ZPFOU,*AQ8CU1+KWBRYGFEO* =(P%T0:'" 18)$ MP8'F0S+,Y:G80(%!4X>!$,'*+$NJ"L0"Q*..+D5H@^0?J$:"@8W@TO'J%*7< M1A?HBVM1_-"89;(>_!(AA\M*'L,.6*90-B-WROG"]UB6=)SEW %CM@$HZ?L4 M*Q#&C#U)*+#?!S%XC/L6@!S2"3%,7#J=VJ8U43,5 Y@=5@^WLFX!]]3UP0&L MD <%+X OA310DH[OQ>8BL8?"6B*@8Q0[EXF L*"^6DHL^(=$:@$A[A-'"CR" M;T@+#B\CUR*$&CY#M8RJ#.JEXT7M%V3B"UFM6>;0%'+3XYXJ[(!ZJ7R+'B+B M?96.X/,@!EG&,8%2$ DZ2#73@C(%B<(B4W*&^[H.<^GY.$>UUYTA8TV8@.:# MC\(-\:@]>ZF=R*9EXP&+0=RN">-T96'$-5V&[_Y4*H!]I\ Z)0,##S[UU" , M1Y*IG*=\"#@+'R'<*3PQ //O#^1%P?2!#6Z@/TGM %T"RS-4<+G%E ETE *J M--QHBA#ELJOBE.2@8F#4F#P06!_P1QB, L*B',MU=*\!WX("-@Q,0'[PCKG) M'I;KMN&#RT;0H1Q(N]/,,)MJEM)A8)Y4/UG_\E!EP'M;X+5P==:B(XY*!7;M M6TJC%0FNP[D9BB_T'B$AJ+$@?1 *^'AF 6,HJ*]L VB38)X,Z'.&IKXWE:JT MU%Q0_#.H7_&,0Z"@QW$-#.EQ@+EAK)DYBGDU@_M]CP[!KR OX)ODBXZ"Q5=6 M* M&C74T-$GI,^"* 8%\HFP*OT9"H&]CM,?C&#BE61A4M.DJ/P@G3]3<,751 M]*5VE(- ;C";]5")PO7XB&(HR1\_9CC*S\X"OE")AN/-Q!MGG8L;,8+1J1U@ M )7R"BP6[LI#J/)X222-@&$*D%*E<:!^-O8/')_'! ),MB .H >3%A8)6U$M ML<$[Q_TZ"5/!P*_,4ZL'BP@Q M-H4^8H&HJ=)@ODH\WQ[1P!WTJ&DA%<@ZJ<&@OP; !-R@?J#OX*+$'C#'E,D% MZ@:SP5ATED@6AFD+NW88A-"-P8PF1)[PXA?>.[98 ?LGTX+2]*!5E>%'$7/ER7NA3I M_2.5TT9?Y.QR6"5T6XUHB7!.(0\BA4I8LB11^LF7;P5!S5VD]M.4VGLUC"AZ MN\P5 <%Y!3Q*L%RP:#404,=Y4...0AI4)I%(BI1'>&*!QV#%LC_0'3_BJ=3Y M S!=!\.!!>EJ)"? M!^5GHTAR'+4>20@:.-"H /M@0S8CQBE[\I(!OQ8D2VI M>HJ[C-[!-"VY%A38(3ICT%(#!31G6 M1(4TN6&7V0\F%%N(/2M3?*6VLKW-%C4TBVH"0D*Z L.440LB89P8PV&*07++ MF:!W3!WKF)W^P$CARDFY/ES592!$I[&<.ZH^G&"!RY&9/1$LK1G!6Z"B%<2\ MD6 !(=TI&C?FAHS'\C_,_:158Q-=Y9:HH\Y<_#?C&>SV:K07.#JT3F.M^ L: M:[.)OEI[;0G*%VRRO50[:=DFQ_:[3OWZ\U6K^PKX7N=,6O2-=RJ_B60""PO8 MJ9VD%>R]I%4WP[>DL^>R<6;RX'5QB >2/ Y4J')5IEAL0*T>^C@$)+U9, "C M"O.Q+)+P('8,',_\"57Q2S/F=WK/Q5IOIY)[V1?WSN0X0\]K^X;6[E.TCQI9#5R*)!)7PI MY))78[TP_ O7%GSHBT/>/FT)^I9= ?B)8ERQ"!*5VAZY'&2;V7^JU%X/\I/2BR>; MY"64@[)S+$OHQL!D/:B"P]?,7,C7S'CDM=^P\HHE8NF87+BRVJV2CY2+WZ=B M?+T]$CE\_[2-;?,_5?XX._.*M^V6['N^;%]]OA7^7/K9;]H_+)9W>- M6^/B_O3=YP\7S;^^>)T6D,+^^O:Q]/YSYUNQ^]6XNS^T]OV#EEZN'[7.G9_] M;KM0:5T? MOE4L^5]02P$"% ,4 " !N1)I7?W>57"D# #C"P $0 M@ $ :6UM=2TR,#(S,3(R,BYX&UL M4$L! A0#% @ ;D2:5Y')>;-4!P U5< !4 ( !B X M &EM;74M,C R,S$R,C)?<')E+GAM;%!+ 0(4 Q0 ( &Y$FE?W.4-O(!< M (-P 2 " 0\6 !T;3(S,S,V.#)D,5\X:RYH=&U02P4& 2 0 ! % 0 7RT end